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Gastroesophageal varices are present in approximately
50% of patients with cirrhosis and variceal hemorrhage
occurs at a rate of about 10%–15% per year (N Engl J Med
1988;319:983–989; Gastrointest Endosc 2007;65:82–88).
Nonselective beta-blockers (NSBB) or variceal band ligation
are currently recommended as primary prophylaxis against
variceal hemorrhage in patients with large or high-risk
varices (J Hepatol 2015;63:743–752; Hepatology
2017;65:310–335). The goal of NSBB therapy is to reduce
portal pressures, which can formally be assessed by
measuring the hepatic venous pressure gradient (HVPG). In
lieu of HVPG, which is invasive and costly, current treatment
guidelines recommend dose titration to target heart rate
and blood pressures (Hepatology 2017;65:310–335). How-
ever, achieving these target vital signs does not necessarily
reflect portal pressure response (Hepatol Int 2018;12:68–
80). This has led to investigations of noninvasive markers of
portal hypertension (Gastroenterology 2012;143:646–654;
Liver Int 2013;33:62–71; J Hepatol 2014;60:1158–1164;
Radiology 2015;275:589–598; J Hepatol 2015;62:1068–
1075; Radiology 2016;279:609–619). The authors of the
current study aimed to develop a model based on nonin-
vasive markers to predict hemodynamic response to NSBB
for primary esophageal variceal hemorrhage prophylaxis in
patients with cirrhosis.
Kim et al performed a single-center, prospective, proof-
of-concept cohort study in adult patients with cirrhosis,
high-risk varices without prior bleeding or variceal band
ligation, and a baseline HVPG of >12 mm Hg. Patients withactive alcohol use, severe decompensated liver disease (eg,
refractory ascites, uncontrolled hepatic encephalopathy), or
contraindications to NSBBs were excluded. High-risk varices
were defined as medium or large varices, small varices with
red wale signs, or varices in patients with Child-Pugh class C
disease. Patients were treated with carvedilol titrated to
target heart rate and blood pressure. Liver stiffness (LS) and
spleen stiffness (SS) were measured using acoustic radiation
force impulse imaging (ie, transient elastography). All pa-
tients included in the analysis underwent LS, SS, and HVPG
measurements in a paired fashion before carvedilol initia-
tion and within 2 weeks after dose titration. Hemodynamic
response was defined as either a decrease in HVPG by
20% of the baseline value or an absolute value of HVPG
<12 mm Hg after dose titration.
The authors aimed to derive a prediction model for he-
modynamic response to NSBB, which was then externally
validated using a second, independent, prospective cohort,
which was well-matched in clinical characteristics to the
development cohort. The mean age of patients in the 2 co-
horts were similar at 58.7 and 57.5 years and most patients
were male, had liver disease owing to chronic hepatitis B
and alcohol use, and had Child-Pugh class A or B disease.
Mean Model for End-stage Liver Disease scores were 9.51
and 9.15. Hemodynamic response occurred in 59 patients
(56%) in the derivation cohort.
In the derivation cohort, the authors identified several
features associated with hemodynamic response, and vari-
ables that were significantly associated with hemodynamic
response in the bivariable analysis (P < .1) were considered
for their final model. Follow-up LS, follow-up SS, and change
in SS before and after carvedilol titration were included in
the multivariate analysis and model assessment process.
Ultimately, only change in SS was predictive of hemody-
namic response to NSBB. The prediction model was
ModelDSS ¼ 0.0490  2.8345  DSS with score ¼ (exp
[ModelDSS]) / (1þexp[ModelDSS]). Using a threshold value of
0.530, the model performed with an area under the curve of
0.803. The sensitivity, specificity, accuracy, and positive and
negative likelihood ratios for predicting hemodynamic
response were 0.814, 0.745, 0.783, 3.192, and 0.250,
respectively. When applied to the validation cohort of 63
patients with 33 patients (52%) achieving hemodynamic
response, the prediction model performed slightly better
with an area under the curve of 0.848 and similar sensi-
tivity, specificity, and accuracy. The authors concluded that
a prediction model using change in SS could be used as a
noninvasive predictor for hemodynamic response to NSBBs
in the setting of esophageal variceal hemorrhage prophy-
laxis in patients with cirrhosis and high-risk esophageal
varices. Of note, the authors also measured secondary out-
comes including all-cause and portal hypertensive gastro-
intestinal bleeding, liver decompensation (ascites,
spontaneous bacterial peritonitis, and hepatic encephalop-
athy), liver transplantation, and mortality. After excluding
patients with alcohol recidivism and NSBB noncompliance,
there was no difference in portal hypertensive bleeding
based on hemodynamic response status in the derivation
cohort; however, portal hypertensive bleeding occurred 
more frequently in hemodynamic nonresponders compared 
with responders (28.0% vs 3.8%) in the validation cohort.
Comment. Measurement of the HVPG remains the gold 
standard for assessing portal hypertension in patients with 
cirrhosis and provides prognostic information on risk 
of decompensation and death (Gastroenterology 1998; 
114:1296–1303; Hepatology 1999;30:1393–1397; N Engl J 
Med 2005;353:2254–2261; Aliment Pharmacol Ther 
2007;25:841–848; Scand J Gastroenterol 2013;48:487–495). 
Change in HVPG can be used as a research or clinical tool, 
including to assess hemodynamic response to NSBBs for 
prophylaxis against variceal hemorrhage (Gastroenterology 
1990;99:1401–1407; Lancet 1995;346:1056–1059). Howev-
er, direct measurement of HVPG is an invasive procedure that 
carries risks, is only available in specialized centers, and is 
expensive (Aliment Pharmacol Ther 2004;19:571–581; Nat 
Rev Gastroenterol Hepatol 2009;6:573–582). The authors of 
this study should be applauded for developing an externally 
validated predictive model, which provides further evidence 
supporting SS as a potential alternative to HVPG. However, 
more work is needed before SS measurement by transient 
elastography becomes the principal noninvasive measure of 
portal pressures in patients with cirrhosis.
Other noninvasive measures have been evaluated and 
used for risk stratification in portal hypertension. LS, as 
measured by transient elastography, predicts presence of 
esophageal varices and correlates with HVPG measurements 
(Liver Int 2013;33:62–71). As a result, LS in combination 
with platelet count is now incorporated in recommenda-
tions from the American Association for the Study of the 
Liver and Baveno VI workshop to identify low-risk patients 
who do not require surveillance endoscopy (J Hepatol 
2015;63:743–752; Hepatology 2017;65:310–335). Howev-
er, LS does not accurately predict portal pressures and is 
particularly inaccurate in patients with severe portal hy-
pertension (Hepatology 2007;45:1290–1297; J Hepatol 
2012;56:696–703). Unlike LS, which only captures hepatic 
resistance and liver fibrosis, SS may also reflect blood flow 
in the portal system and portal hypertension-induced 
splenic fibrosis (Hepatology 2007;45:1290–1297; J Hep-
atol 2010;52:529–539). The biologic plausibility of SS is 
reinforced by data suggesting that SS outperforms LS in the 
prediction of the presence of esophageal varices and portal 
hypertension (Gastroenterology 2012;143:646–654; PLoS 
One 2016;11:e0165786).
Despite the supporting evidence for the measurement of 
SS, it was not clear that this was the a priori hypothesis of 
these authors based on their methodology of model devel-
opment, or how initial candidate covariates were chosen for 
consideration in their model. The use of binary logistic 
regression to identify variables associated with carvedilol 
response based on P values increases the risk of inappro-
priate exclusion of variables in their multivariable analysis 
(J Clin Epidemiol 1996;49:907–916). The performance of 
their model in the external validation cohort is somewhat 
reassuring, but their sample size in this independent cohort 
is still smaller than the minimum 100 events recommendedfor external validation cohorts (Stat Med 2016;35:214–226).
Their external validation may, therefore, have been inca-
pable of detecting sizable decreases in model performance.
The generalizability of the findings is also a potential
issue. Greater interobserver variability has been reported
for SS compared with LS measurements and these authors
relied on a single, experienced radiologist for elastography
measurements (Eur Radiol 2014;24:1283–1289). The het-
erogeneity of SS measurements, particularly in patients with
small spleens, may explain why prior external validation
efforts found that SS was an inaccurate measure of HVPG
(Aliment Pharmacol Ther 2018;47:621–630; Aliment Phar-
macol Ther 2018;47:856–857). Kim et al’s use of a single,
experienced radiologist also undermines one of the main
advantages of SS over HVPG, which is its accessibility
outside of specialized centers. Furthermore, this study,
which was performed in a Korean population, included few
patients with nonalcoholic fatty liver disease, which is the
most common cause of chronic liver disease in the Western
world (Clin Gastroenterol Hepatol 2016;14:301–308 e301–
302; Nat Rev Gastroenterol Hepatol 2018;15:11–20). LS
measurements are less accurate in obese patients owing to
attenuation of elastic and ultrasound waves (Hepatology
2010;51:828–835). Even with newer probes specifically
designed for and validated in patients with nonalcoholic
fatty liver disease, the accuracy and reliability of measure-
ments are lower in obese patients (Am J Gastroenterol
2012;107:1862–1871; J Hepatol 2018;69:878–885). In this
study, failure to measure SS was only reported in 2 patients
owing to “anatomical difficulty,” likely reflective of their
relatively low BMI (mean 24 kg/m2). It is likely that this
failure rate would be considerably higher in Western
populations.
Several other points bear mentioning. First, a number of
patients were excluded from the analysis, including those
with ongoing alcohol use or adverse effects of NSBBs and,
unfortunately, results are not reported for these individuals.
Therefore, these results represent the best case scenario for
the performance of the model. For this proof-of-concept
study, it may reasonable to limit the population to those
most likely to benefit. However, validation of this model in a
population with these patients included would increase the
clinical applicability of these findings. Second, the current
model cannot be used (although it was not necessarily
intended to be used) at baseline before starting a beta-
blocker regimen. Ideally, it would be optimal to determine
who is most likely to respond before starting the NSBBs and
subjecting patients to potential adverse events without
benefit. Third, the authors are to be commended for
attempting to track important clinical outcomes such as
variceal hemorrhage. Noninvasive measures of portal pres-
sures, such as SS, must be shown to predict patient-centered
outcomes such as gastrointestinal bleeding, rather than in-
direct measures such as HVPG, before they are broadly
adopted in clinical practice. In future studies, these could be
the key outcome metric to determine if this predictive
model is linked to real-world complications.
Despite its potential pitfalls, the study by Kim et al
provides valuable evidence that quantification of SS may
one day serve a role in clinical practice. Unlike prior studies 
examining the correlation between SS and HVPG, the au-
thors examined its ability to predict hemodynamic response 
to carvedilol, a more clinically relevant question (Gastro-
enterology 2012;143:646–654; Liver Int 2017;37:396–405). 
Furthermore, after excluding those with alcohol recidivism 
and noncompliance (in what is essentially a per-protocol 
analysis), portal hypertension-related bleeding was signifi-
cantly lower among hemodynamic responders in their 
validation cohort. This finding suggests that change in SS 
may correlate with a decrease in important clinical out-
comes. However, pending external validation in more 
representative settings, SS is not yet ready for a move from 
the research to clinical world.
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